Kim Kyung Han, Baek Yang-Hyun, Kang Yeo Wool, Yoon Byeol-A, Moon Sang Yi
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Department of Neurology, Dong-A University College of Medicine, Busan, Korea.
Korean J Gastroenterol. 2023 Jul 25;82(1):35-39. doi: 10.4166/kjg.2023.054.
The results of the IMbrave150 study have led to widespread use of the combination therapy of atezolizumab and bevacizumab as a first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). Compared to traditional cytotoxic chemotherapy agents, immune checkpoint inhibitors show a spectrum of side effects ranging from mild side effects such as skin rash to potentially severe systemic effects such as myocarditis. We present a case of transverse myelitis diagnosed during the treatment of HCC with atezolizumab and bevacizumab combination therapy.
IMbrave150研究的结果已导致阿替利珠单抗和贝伐单抗联合疗法被广泛用作不可切除或转移性肝细胞癌（HCC）的一线治疗方法。与传统的细胞毒性化疗药物相比，免疫检查点抑制剂显示出一系列副作用，从轻微的副作用如皮疹到潜在的严重全身效应如心肌炎。我们报告一例在使用阿替利珠单抗和贝伐单抗联合疗法治疗HCC期间诊断出的横贯性脊髓炎病例。
